Downloads: 97

Files in This Item:
File Description SizeFormat 
cam4.974.pdf196.02 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSakamoto, Soichiroen
dc.contributor.authorKawabata, Hiroshien
dc.contributor.authorKanda, Junyaen
dc.contributor.authorUchiyama, Tatsukien
dc.contributor.authorMizumoto, Chisakien
dc.contributor.authorKitano, Toshiyukien
dc.contributor.authorKondo, Tadakazuen
dc.contributor.authorHishizawa, Masakatsuen
dc.contributor.authorTomosugi, Naohisaen
dc.contributor.authorTakaori-Kondo, Akifumien
dc.contributor.alternative川端, 浩ja
dc.date.accessioned2017-03-09T07:26:39Z-
dc.date.available2017-03-09T07:26:39Z-
dc.date.issued2017-01-
dc.identifier.issn2045-7634-
dc.identifier.urihttp://hdl.handle.net/2433/218756-
dc.description.abstractIron overload is considered a risk factor for mortality in patients with hematopoietic malignancies. Hepcidin is a key regulator of systemic iron balance. We previously reported dynamic changes of serum hepcidin-25 levels in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we retrospectively analyzed the association of pretransplant hepcidin-25 levels with overall survival (OS), engraftment, and other clinical outcomes of allo-HSCT in patients with hematologic malignancies. A total of 166 patients were divided into two groups depending on their pretransplant serum hepcidin-25 levels; their median age was 49.5 years, and the median follow-up time was 46.8 months. At 3 years, the patients in the high-hepcidin group had a significantly lower OS than those in the low-hepcidin group (49.2 vs. 69.0%, respectively; P = 0.006). Multivariate analysis revealed that pretransplant serum hepcidin-25 level, sex, and disease status were independently associated with OS. The incidence of platelet engraftment was significantly lower in the high-hepcidin group than in the low-hepcidin group, whereas no significant differences were observed in neutrophil and reticulocyte engraftments between these groups. Hence, pretransplant serum hepcidin levels can be a marker for predicting delayed platelet recovery after allo-HSCen
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherWiley-Blackwellen
dc.rights© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.en
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en
dc.subjectAllogeneic hematopoietic stem cell transplantationen
dc.subjectengraftmenten
dc.subjecthepcidinen
dc.subjectironen
dc.titleHigh pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantationen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleCancer Medicineen
dc.identifier.volume6-
dc.identifier.issue1-
dc.identifier.spage120-
dc.identifier.epage128-
dc.relation.doi10.1002/cam4.974-
dc.textversionpublisher-
dc.identifier.pmid27905193-
dcterms.accessRightsopen access-
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.